Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Receivables (2016 - 2022)

Agios Pharmaceuticals (AGIO) has disclosed Receivables for 9 consecutive years, with $2.2 million as the latest value for Q4 2022.

  • For Q4 2022, Receivables fell 49.61% year-over-year to $2.2 million; the TTM value through Dec 2022 reached $2.2 million, down 49.61%, while the annual FY2022 figure was $2.2 million, 49.61% down from the prior year.
  • Receivables hit $2.2 million in Q4 2022 for Agios Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Across five years, Receivables topped out at $21.3 million in Q3 2020 and bottomed at $2.2 million in Q4 2022.
  • Average Receivables over 5 years is $10.2 million, with a median of $8.9 million recorded in 2019.
  • On a YoY basis, Receivables climbed as much as 251.65% in 2018 and fell as far as 52.27% in 2018.
  • Agios Pharmaceuticals' Receivables stood at $7.5 million in 2018, then soared by 39.17% to $10.5 million in 2019, then soared by 103.25% to $21.3 million in 2020, then crashed by 79.47% to $4.4 million in 2021, then tumbled by 49.61% to $2.2 million in 2022.
  • According to Business Quant data, Receivables over the past three periods came in at $2.2 million, $4.4 million, and $21.3 million for Q4 2022, Q4 2021, and Q3 2020 respectively.